Herpes Zoster
An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed)
Subtype terms (3)
More specific conditions that are subtypes of Herpes Zoster in the MeSH hierarchy.
Drugs by status
Approved for this indication (4)
Phase 4 trials (6)
Phase 3 trials (16)
- 23-valent pneumococcal polysaccharide vaccine
- diphtheria, tetanus and whole cell pertussis vaccine
- capsaicin
- fv-100
- gsk2186877a
- pneumococcal 13-valent conjugate vaccine
- live, attenuated herpes zoster vaccine
- inactivated influenza vaccine
- v212
- methadone
- morphine
- nortriptyline
- desipramine
- amenamevir
- interferon alpha-2b
- mrna-1273
Phase 2 trials (18)
Phase 1 trials (8)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (47)
- AstraZeneca
- Merck
- Sanofi
- Sanofi-Aventis
- Changchun Keygen Biological Products Co., Ltd.
- GlaxoSmithKline
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Yung Shin Pharm. Ind. Co., Ltd.
- ZonMw: The Netherlands Organisation for Health Research and Development
- National Institutes of Health (NIH)
- National Eye Institute (NEI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute on Aging (NIA)
- Region Skane
- Boston University
- Chulalongkorn University
- Duke University
- University of Washington
- New York University
- Radboud University
- Stanford University
- Tanta University
- The Guenther Dermatology Research Centre
- The HIV Netherlands Australia Thailand Research Collaboration
- Tulane University
- University of Toronto
- B.P. Koirala Institute of Health Sciences
- Peking University
- Taichung Veterans General Hospital
- University of Colorado, Denver
- +17 more
Organization Involved with Phase 3 Indications (15)
- Changchun BCHT Biotechnology Co.
- Hepion Pharmaceuticals
- Maruho Co., Ltd.
- Mundipharma
- Sinovac Biotech Co., Ltd
- National Center for Research Resources (NCRR)
- National Institute of Neurological Disorders and Stroke (NINDS)
- Johns Hopkins University
- Korea University
- De La Salle University
- University of Sao Paulo
- EMS S/A
- NeurogesX
- SK Chemicals
- University of Geneva
Organization Involved with Phase 2 Indications (25)
- Bristol-Myers Squibb
- Astellas
- Bausch & Lomb
- Pfizer
- aRigen Pharmaceuticals, Inc.
- Kalypsys, Inc.
- Arvelle
- Epiphany Biosciences
- Nobel Pharmaceuticals
- Renovis
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Dental and Craniofacial Research (NIDCR)
- Shahid Beheshti University of Medical Sciences
- Emory University
- Northwestern University
- Oregon Health and Science University
- University of Sydney
- University of Zurich
- Capital Medical University
- University of California, San Diego
- University of California, San Francisco
- University of Texas at Houston
- University of Alabama, Birmingham
- Adult AIDS Clinical Trials Group
- Johnson and Johnson
Organization Involved with Phase 1 Indications (16)
- Green Cross Corporation
- Centrexion Therapeutics
- Immune Design
- Oklahoma Medical Research Foundation
- Baylor University
- University of Oklahoma
- University of Rochester
- University of Cincinnati
- Nucleus Network Ltd
- The Center for Pharmaceutical Research
- North American Pediatric Renal Transplantation Study (NAPRTCS)
- Novotech
- Cooperative Clinical Trials in Pediatric Transplantation
- Mogam Biotechnology Research Institute
- Curevo Inc
- EyeGene Inc.
Organization Involved with Other Experimental Indications (10)